- Location
Servier
"-
XOMA Received Orphan Drug Designation for Its IL-1 Beta Modulating Antibody 'Gevokizumab'
Feb 27, 2014US-based XOMA Corporation (XOMA) has received Orphan Drug Designation from the US Food and Drug Administration (FDA) for its IL-1 beta modulating antibody 'gevokizumab' for the treatment of pyoderma gangrenosum (PG). Gevokizumab is a ...
Tags: Orphan Drug, Medicine
-
Their Joint Aim Is to Identify New Therapeutic Targets in 'Triple Negative' Breast Cancers
Feb 7, 2014Their joint aim is to identify new therapeutic targets in ‘triple negative’ breast cancers Curie-Cancer, the body which leads the Institut Curie's industry partner research activity, and Servier, today announce that they have ...
Tags: triple negative, Curie-Cancer, TTK/MPS1, Institut Curie and Servier
-
Galapagos Delivered The First Pre-Clinical Candidate Compound in Its Alliance with Servier
Nov 28, 2012Galapagos, a mid-size biotechnology company, has delivered the first pre-clinical candidate compound in its osteoarthritis alliance with Servier. Servier and Galapagos entered into an alliance in July 2010 to develop new oral medicines ...
Tags: Galapagos Identifies Drug, Galapagos, Servier, osteoarthritis
-
Vernalis Has Reached a Research Milestone with Servier
Nov 28, 2012Vernalis has reached a research milestone as part of the oncology drug discovery alliance with French pharmaceutical company, Servier. Under the drug discovery program, Vernalis will receive a payment of €0.5m from Servier on ...
Tags: drug discovery platforms, oncology drug discovery, undisclosed oncology
